Table 4.
17β-estradiol (E)-regulated genes involved in E-induced proliferation
| E-treated animals | All animals | E-regulated | ||||||
|---|---|---|---|---|---|---|---|---|
| Gene | BrDU slope | BrDU P | BrDU R2 | BrDU slope | BrDU P | BrDU R2 | P | Gene name |
| ANLN | 16.34 | 1.17E-04 | 0.67 | 5.72 | 3.61E-08 | 0.64 | 3.28E-09 | Anillin actin binding protein |
| BUB1 | 11.36 | 2.99E-04 | 0.62 | 6.27 | 7.78E-09 | 0.68 | 1.26E-09 | BUB1 mitotic checkpoint serine/threonine kinase |
| CD99L2 | –18.75 | 8.19E-05 | 0.68 | –23.00 | 1.09E-06 | 0.55 | 1.95E-04 | CD99 molecule-like 2 |
| CDK1 | 8.57 | 1.36E-04 | 0.66 | 3.81 | 1.07E-08 | 0.67 | 1.42E-09 | Cyclin dependent kinase 1 |
| CENPF | 8.48 | 3.73E-04 | 0.61 | 4.57 | 1.59E-08 | 0.66 | 1.11E-08 | Centromere protein F |
| CKAP2 | 10.26 | 3.35E-05 | 0.72 | 5.34 | 3.74E-09 | 0.69 | 5.45E-09 | Cytoskeleton-associated protein 2 |
| CLSPN | 11.76 | 8.38E-05 | 0.68 | 8.00 | 8.04E-09 | 0.68 | 1.86E-08 | Claspin |
| DDIT3 | –20.44 | 2.87E-04 | 0.62 | –17.80 | 2.09E-06 | 0.53 | 3.47E-05 | DNA damage-inducible transcript 3 |
| DLGAP5 | 7.43 | 3.44E-04 | 0.61 | 4.63 | 1.50E-08 | 0.66 | 1.70E-08 | DLG-associated protein 5 |
| ENDOU | –8.21 | 4.41E-04 | 0.60 | –7.67 | 1.84E-08 | 0.66 | 1.67E-06 | Endonuclease, poly(U) specific |
| ENO2 | –12.43 | 2.55E-04 | 0.63 | –7.98 | 3.84E-07 | 0.58 | 6.37E-06 | Enolase 2 |
| GAS6 | –16.59 | 1.24E-04 | 0.66 | –9.28 | 2.41E-07 | 0.59 | 1.18E-06 | Growth arrest specific 6 |
| HEBP1 | –18.34 | 1.15E-04 | 0.67 | –21.45 | 4.93E-08 | 0.63 | 2.73E-05 | Heme binding protein |
| HMMR | 7.77 | 2.46E-04 | 0.63 | 3.75 | 3.86E-06 | 0.51 | 7.51E-06 | Hyaluronan-mediated motility receptor |
| KIF23 | 9.62 | 2.59E-04 | 0.63 | 4.39 | 8.56E-08 | 0.62 | 1.22E-09 | Kinesin family member 23 |
| KNL1 | 10.20 | 2.02E-04 | 0.64 | 4.56 | 6.43E-08 | 0.63 | 2.83E-08 | Kinetochore scaffold 1 |
| NBL1 | –9.70 | 2.34E-05 | 0.73 | –7.78 | 2.36E-07 | 0.60 | 5.99E-05 | Neuroblastoma 1, DAN family BMP antagonist |
| NCAPG | 9.15 | 3.56E-04 | 0.61 | 4.53 | 6.96E-08 | 0.63 | 1.45E-08 | Non-SMC condensin I complex subunit G |
| NUF2 | 8.89 | 2.33E-04 | 0.63 | 5.78 | 1.12E-07 | 0.61 | 1.31E-07 | NUF2, NDC80 kinetochore complex component |
| PDGFRL | –14.77 | 4.04E-04 | 0.60 | –12.43 | 7.41E-09 | 0.68 | 2.87E-07 | Platelet-derived growth factor receptor like |
| RORA | –10.60 | 2.27E-04 | 0.63 | –6.36 | 1.12E-05 | 0.48 | 1.64E-04 | RAR related orphan receptor A |
| SKA1 | 7.68 | 2.54E-04 | 0.63 | 4.35 | 7.94E-08 | 0.62 | 6.34E-08 | Spindle and kinetochore associated complex subunit 1 |
| SKA2 | 19.92 | 7.63E-06 | 0.77 | 9.56 | 1.18E-07 | 0.61 | 4.50E-07 | Spindle and kinetochore associated complex subunit 2 |
| SMC2 | 11.40 | 1.16E-04 | 0.67 | 10.41 | 2.87E-07 | 0.59 | 1.12E-04 | Structural maintenance of chromosomes 2 |
| SMOC2 | –10.76 | 2.31E-04 | 0.63 | –9.32 | 7.16E-07 | 0.56 | 7.53E-05 | SPARC-related modular calcium-binding protein 2 |
| TPPP | –8.59 | 2.71E-04 | 0.62 | –6.92 | 6.49E-08 | 0.63 | 2.21E-06 | Tubulin polymerization promoting protein |
| VRK1 | 14.90 | 3.89E-04 | 0.61 | 11.73 | 1.49E-07 | 0.61 | 4.90E-06 | VRK serine/threonine kinase 1 |
| YPEL3 | –15.35 | 2.04E-04 | 0.64 | –12.57 | 2.72E-08 | 0.65 | 4.38E-07 | Yippee-like 3 |
| ZBTB47 | –15.72 | 1.20E-04 | 0.66 | –15.00 | 5.83E-08 | 0.63 | 3.66E-05 | Zinc finger and BTB domain containing 47 |
Gene expression data from all ovariectomized hormone-treated animals (n = 32) was analyzed by analysis of variance to identify the main effect of E (FDR < 0.01), which was then regressed against %BrDU-positive cells from immunohistochemistry data to extract statistically significant linear relationships (FDR < 0.01). Next, gene expression data from only E-treated animals (n = 16) was regressed against %BrDU-positive cells. Genes that were E-regulated and statistically significantly associated with %BrDU-positive cells in both regressions are shown. Underlining indicates genes with an annotation of cell cycle, mitosis, or centrosomes. Slope, linear regression slope are shown for each gene.
Abbreviations: %BrDU, percentage of 5-bromo-2-deoxyuridine; E, 17β-estradiol; FDR, false discovery rate.